IFNG and melanoma: For instance, the DONIMI trial used a baseline IFN-γ signature to stratify melanoma patients for neoadjuvant immunotherapy, demonstrating that patients with high IFN-γ scores derived benefit from PD-1 monotherapy, whereas low-score tumors might require intensified therapy [105].